Immunome, Inc.

NASDAQ:IMNM

Biotechnology

Healthcare
$17.18 -2.26%

-$0.42 today

Market cap
$2.03B
Beta
2.07
P/E (TTM)
-9.1
EPS (TTM)
-$1.99
52W Low $7.96High $27.65

Volume 1.03M

Average 1.23M

IMNM Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Immunome, Inc.NASDAQ: IMNM

Research & Development · Q3 FY2026 · quarter ended Sep 2026

Research & development growth accelerates

Q3 FY2026 research & development of $69.51M rose 41.3% year over year, ahead of the +35.6% change in trailing-twelve-month research & development. Sequentially, it rose 16.1% from the prior quarter. Over 3 fiscal years it compounded at +95.7% a year.

Context

  • Research & development amounted to 2511.6% of revenue in FY2025, up 1078.8 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +41.3% holds above the trailing-twelve-month pace of +35.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$69.51M+16.1% QoQ
Last fiscal yearDec 2025
$174.33M+34.6% YoY
LTMSep 2026
$236.54M+35.6% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+41.3%——
1 year+34.6%——
3-year CAGR+95.7%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
174.33M USD
Year-over-year change
+34.6%
4-year CAGR
+87.5%

Research & Development vs competitors

How IMNM compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +35.6% is the 4th highest of 11, against a peer median of +22.3%.
  • Over three fiscal years its annual growth of +95.7% compares with a peer median of +27.1%.
IMNM Competitors
Research & Development for IMNM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$283.32M USD+31.2%+43.9%252960.7%
IMCRImmunocore Holdings plcLTM Mar 2026$259.11M USD+17.2%+34.4%67.2%
IMNMImmunome, Inc.LTM Sep 2026$236.54M USD+35.6%+95.7%—
BCYCBicycle Therapeutics plcLTM Mar 2026$230.13M USD+16.7%+43.3%362.4%
IMTXImmatics N.V.LTM Mar 2026€201.11M EUR+27.4%+19.9%539.2%
STROSutro Biopharma, Inc.LTM Mar 2026$151.37M USD-38.7%+6.7%152.0%
MGNXMacroGenics, Inc.LTM Mar 2026$135.36M USD-19.9%-12.2%86.2%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$129.68M USD+5.2%+71.4%—
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$37.44M USD+64.5%+11.3%—
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$23.16M USD+47.2%-19.1%—
IMMXImmix Biopharma, Inc.LTM Mar 2026$20.26M USD+102.3%+57.1%—
Peer median (excluding IMNM) —+22.3%+27.1%257.2%

Competitors are the stored peer set for IMNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0014.02M9.04M6.94M
Cost of Revenue00002.96M
Gross Profit0014.02M9.04M3.99M
Gross Margin——100.0%100.0%57.4%
Research & Development14.11M23.27M23.09M129.54M174.33M
Selling, General & Admin11.09M13.63M19.66M32.96M43.77M
Operating Expenses25.2M36.9M123.55M314.84M218.1M
Depreciation & Amortization755K631K728K2.1M2.96M
EBITDA(23.95M)(36.26M)(28M)(151.35M)(209.44M)
EBITDA Margin——-199.7%-1674.1%-3017.4%
Operating Income(25.2M)(36.9M)(109.53M)(305.8M)(214.11M)
Operating Margin——-781.4%-3382.4%-3084.8%
Interest Income10K5K2.72M12.84M11.72M
Interest Expense10K5K000
Other Income / Expenses493K5K2.72M12.84M1.72M
Income Before Tax(24.71M)(36.9M)(106.81M)(292.96M)(212.39M)
Pre-Tax Margin——-761.9%-3240.4%-3060.0%
Income Tax Expense00000
Net Income(24.71M)(36.9M)(106.81M)(292.96M)(212.39M)
Net Margin——-761.9%-3240.4%-3060.0%
EPS (Basic)(2.14)(3.09)(5.38)(5.00)(2.43)
EPS (Diluted)(2.14)(3.09)(5.38)(5.00)(2.43)
Weighted Avg Shares11.54M12.13M19.84M58.64M87.35M
Weighted Avg Shares (Diluted)11.54M12.13M19.84M58.64M87.35M

Immunome, Inc.

NASDAQ:IMNM

Intrinsic Alpha fair value

Locked

Current Price

$17.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.